Monday, July 1, 2013

Thomson Reuters brings new technology to the clinical trials game

Cortellis™ Clinical Trials Intelligence is a new platform created by Thompson Reuters to allow access to over 130,000 clinical trials on a variety of illnesses areas including biologics, diagnostics, treating drugs with rare diseases and more. In addition, it offers access to many news article, press releases and information that Thompson Reuters has access to as one of the world's leading information providers according to the Sacramento Bee.

Cortellis Site Performance Advisor is a tool that allows companies to analyze the best places to conduct their clinical trials that takes into account patient populations and what countries and locations are best.

Reuters is striving for these two platforms to optimize clinical trials, decrease time to market, accelerate clinical trial development and maximize portfolio strategies for professionals in clinical operations and development, R&D benchmarking, R&D strategy, strategic resourcing, precision and translational medicine and at contract research organizations (CROs).

Tools like these and more will be discussed this September at the Partnerships in Clinical Trials Asia event.  During the session Optimal Country and Site Selection Factors when Executing Clinical Trials, Ian Lauf, Director, Eisai USA will lead a panel with speakers representing Sanofi Aventis India, Takeda Global Research and Development Center (Asia), and Merck USA to look at what factors should be considered with choosing a site in Asia to conduct a clinical trial.  For more information on this session and the rest of the program, download the agenda.  If you'd like to join us September 4-6, 2013 in Shanghai, as a reader of this blog when you register to join us and mention code XP1875BLOG, you'll save 15% off the standard rate!

Do tools like these better help you locate and evaluate potential sites for your clinical trials?

No comments: